Nuclivision

About Nuclivision

Nuclivision develops radiotracers and software solutions that enhance PET imaging workflows, improving image quality and reducing radiation exposure for oncology patients. The technology addresses long wait times and high costs associated with nuclear medicine, facilitating timely diagnosis and treatment.

<problem> Current PET imaging workflows often involve long wait times, high costs due to expensive radiotracer doses, and potential risks associated with radioactive exposure for oncology patients. These challenges can hinder timely diagnosis and treatment. </problem> <solution> Nuclivision offers software solutions designed to enhance PET imaging, focusing on improving image quality while reducing radiation exposure and optimizing workflows. Their flagship product, Nuclarity, leverages AI to deliver enhanced PET images, boosting patient safety and streamlining operations for more efficient imaging centers. By optimizing image acquisition and processing, Nuclarity assists physicians throughout the entire workflow, from initial scan to diagnosis and follow-up, ultimately tackling the challenges of growing demands, radioactive exposure, and high costs in nuclear medicine. </solution> <features> - AI-driven PET image enhancement to improve image quality - Reduction of radioactive tracer dose during scans - Streamlined workflows for more efficient imaging centers - Assistance for physicians throughout the entire imaging workflow, from acquisition to diagnosis and follow-up </features> <target_audience> The primary target audience includes physicians, nuclear medicine professionals, and hospitals seeking to improve PET imaging workflows, enhance patient safety, and reduce costs. </target_audience>

What does Nuclivision do?

Nuclivision develops radiotracers and software solutions that enhance PET imaging workflows, improving image quality and reducing radiation exposure for oncology patients. The technology addresses long wait times and high costs associated with nuclear medicine, facilitating timely diagnosis and treatment.

Where is Nuclivision located?

Nuclivision is based in Montrose-Ghent, Belgium.

When was Nuclivision founded?

Nuclivision was founded in 2022.

How much funding has Nuclivision raised?

Nuclivision has raised 430000.

Location
Montrose-Ghent, Belgium
Founded
2022
Funding
430000
Employees
10 employees
Major Investors
Lumiares

Find Investable Startups and Competitors

Search thousands of startups using natural language

Nuclivision

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Nuclivision develops radiotracers and software solutions that enhance PET imaging workflows, improving image quality and reducing radiation exposure for oncology patients. The technology addresses long wait times and high costs associated with nuclear medicine, facilitating timely diagnosis and treatment.

nuclivision.com700+
cb
Crunchbase
Founded 2022Montrose-Ghent, Belgium

Funding

$

Estimated Funding

$300K+

Major Investors

Lumiares

Team (10+)

No team information available.

Company Description

Problem

Current PET imaging workflows often involve long wait times, high costs due to expensive radiotracer doses, and potential risks associated with radioactive exposure for oncology patients. These challenges can hinder timely diagnosis and treatment.

Solution

Nuclivision offers software solutions designed to enhance PET imaging, focusing on improving image quality while reducing radiation exposure and optimizing workflows. Their flagship product, Nuclarity, leverages AI to deliver enhanced PET images, boosting patient safety and streamlining operations for more efficient imaging centers. By optimizing image acquisition and processing, Nuclarity assists physicians throughout the entire workflow, from initial scan to diagnosis and follow-up, ultimately tackling the challenges of growing demands, radioactive exposure, and high costs in nuclear medicine.

Features

AI-driven PET image enhancement to improve image quality

Reduction of radioactive tracer dose during scans

Streamlined workflows for more efficient imaging centers

Assistance for physicians throughout the entire imaging workflow, from acquisition to diagnosis and follow-up

Target Audience

The primary target audience includes physicians, nuclear medicine professionals, and hospitals seeking to improve PET imaging workflows, enhance patient safety, and reduce costs.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.